Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial

Martha Kirstine Haahr a,e,f,1, Charlotte Harken Jensen b,e,1, Navid Mohamadpour Toyserkani c,e,f, Ditte Caroline Andersen b,e,f, Per Damkier b,f, Jens Ahn Sørensen c,e,f, Lars Lund a,e,f, Søren Paludan Sheikh b,d,e,*

a Department of Urology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark
b Laboratory of Molecular and Cellular Cardiology, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
c Department of Plastic Surgery, Odense University Hospital, Odense, Denmark
d Institute of Molecular Medicine, University of Southern Denmark, Winoewoerken 21 3rd, 5000 Odense C, Denmark
e The Danish Centre for Regenerative Medicine (www.danishcrm.com); Odense University Hospital, Denmark
f Clinical Institute, University of Southern Denmark, 5000 Odense C, Denmark

ARTICLE INFO

Article history:
Received 25 October 2015
Received in revised form 12 January 2016
Accepted 18 January 2016
Available online 19 January 2016

Keywords:
Adipose-derived regenerative cells
Adipose-derived stromal vascular fraction
Adipose-derived stem cells
Cell therapy
Erectile dysfunction
Clinical trial

ABSTRACT

Background: Prostate cancer is the most common cancer in men, and radical prostatectomy (RP) often results in erectile dysfunction (ED) and a substantially reduced quality of life. The efficacy of current interventions, principal treatment with PDE-5 inhibitors, is not satisfactory and this condition presents an unmet medical need. Preclinical studies using adipose-derived stem cells to treat ED have shown promising results. Herein, we report the results of a human phase 1 trial with autologous adipose-derived regenerative cells (ADRCs) freshly isolated after a liposuction.

Methods: Seventeen men suffering from post RP ED, with no recovery using conventional therapy, were enrolled in a prospective phase 1 open-label and single-arm study. All subjects had RP performed 5–18 months before enrolment, and were followed for 6 months after intracavernosal transplantation. ADRCs were analyzed for the presence of stem cell surface markers, viability and ability to differentiate. Primary endpoint was the safety and tolerance of the cell therapy while the secondary outcome was improvement of erectile function. Any adverse events were reported and erectile function was assessed by IIEF-5 scores. The study is registered with ClinicalTrials.gov, NCT02240823.

Findings: Intracavernous injection of ADRCs was well-tolerated and only minor events related to the liposuction and cell injections were reported at the one-month evaluation, but none at later time points. Overall during the study period, 8 of 17 men recovered their erectile function and were able to accomplish sexual intercourse. Post-hoc stratification according to urinary continence status was performed. Accordingly, for continent men (median IIEF inclusion = 7 (95% CI 5–12)), 8 out of 11 men recovered erectile function (IIEF6 months = 17 (6–23)), corresponding to a mean difference of 0.57 (0.38–0.85; p = 0.0069), versus inclusion. In contrast, incontinent men did not regain erectile function (median IIEF1/3/6 months = 5 (95% CI 5–6); mean difference 1 (95% CI 0.85–1.18); p > 0.9999).

Interpretation: In this phase 1 trial a single intracavernosal injection of freshly isolated autologous ADRCs was a safe procedure. A potential efficacy is suggested by a significant improvement in IIEF-5 scores and erectile function. We suggest that ADRCs represent a promising interventional therapy of ED following prostatectomy.

Funding: Danish Medical Research Council, Odense University Hospital and the Danish Cancer Society.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The promising potential of stem cell therapy for various diseases has been subject to much basic research and has attracted significant clinical interest. In clinical practice, however, such interventions remain largely experimental outside of bone marrow transplantation and autologous stem cell transplantation as related to chemotherapy (Dohner et al., 2015). Clinical implementation of stem cell treatment for erectile dysfunction (ED) represents a plausible candidate for such an approach. It
has been reported that mesenchymal stem cells from bone marrow or adipose tissue can correct ED in animal models (Gimble et al., 2012; Lin et al., 2012). Prostate cancer is the most common male cancer affecting 17% of all men (Chung and Gillman, 2014), of which approximately 25% receive a prostatectomy. Due to penile nerve injury, up to 86% of patients experience ED (Salonia et al., 2012; Tal et al., 2009; Wayne and Albersen, 2014) following prostatectomy. ED is defined as the consistent or recurrent inability to attain or maintain an erection sufficient for satisfactory sexual performance (JAMA, 1993; Montorsi et al., 2010). ED following prostatectomy is an important medical condition that substantially decreases quality of life of the afflicted men and their sexual partners (Litwin et al., 1998). Besides prostatectomy, ED risk factors include widespread diseases such as hypertension and obesity, but also medications such as β-blockers and anti-depressants, as well as major life-style factors like smoking and alcohol use cause ED (Shabsigh et al., 2005). Moreover, age is a risk factor; approximately one third of men in their forties report ED symptoms, while more than half of men over 60 years suffer from ED (Lewis et al., 2010). Although the prevalence and impact of ED remain substantial, current penile rehabilitation therapy following prostatectomy mainly consists of treatment with PDE-5 inhibitors or injection therapy, which have an unimpressive clinical efficacy around 27% or lower (Chung and Gillman, 2014; Wayne and Albersen, 2014; Wayne et al., 2015). This condition therefore presents a significant unmet medical need.

At the cellular level, ED is thought to be caused by neuro-vascular or hormonal dysfunction resulting in impaired vasodilatation of penile arteries (Salonia et al., 2012; Wayne and Albersen, 2014). When the natural nocturnal erection is lost, the penis tissue enters a chronic hypoxic state leading to vascular dysfunction (Mulhall et al., 2010). Adipose-derived regenerative cells (ADRCs, also referred to as stromal vascular fraction, SVF) are able to differentiate into vascular cells and neurons in vitro (Gimble et al., 2013; Lin et al., 2008; Zuk, 2010), and a large body of preclinical work shows a surprisingly good effect of ADRC injection into the corpora cavernosa (Lin et al., 2012). One human study reported improved erectile function using umbilical cord blood cells in 7 diabetic ED patients (Bahk et al., 2010). This latter study demonstrates proof of concept for the use of cell therapy in clinical ED treatment, even if the etiology of ED in diabetics may reflect less nerve injury as compared to patients after radical prostatectomy (RP) (Schauer et al., 2015). The safety of applying freshly isolated autologous ADRCs for non-homologous use in intracavernous injections has not previously been explored.

We here report safety and preliminary efficacy outcomes from a phase 1 clinical trial using autologous ADRCs for the treatment of ED in 17 men after radical prostatectomy.

2. Methods

2.1. Study Design and Eligibility Criteria

Study population (Fig. 1): Seventeen patients with ED after RP (3 open, 14 robot-assisted laparoscopic prostatectomies) were enrolled between May 2014 and September 2015 in this prospective, open-label, single-arm and single-center study. All subjects had RP performed at Odense University Hospital, Denmark, 5–18 months prior to enrollment. Inclusion criteria were: age > 18 years. Clinical follow-up was required to show organ-confined prostate cancer without metastasis. Patients had to be sexually active before RP and expressing a wish to remain sexually active. Appropriate pharmacological intervention (PDE-5 or PGE1 analog) must have been tried and deemed insufficient to allow for inclusion. Patients had to be sexually active before RP and expressing a wish to remain sexually active. Appropriate pharmacological intervention (PDE-5 or PGE1 analog) must have been tried and deemed insufficient to allow for inclusion. The participants were suggested to continue medication throughout the study period if they felt the slightest effect. Patients with no initial effect were encouraged to retry pharmacological treatment, to see if they had changed responder-status. Patients were told to continue other regular medications and pelvic physiotherapy during the trial.

Exclusion criteria: treatment with anticoagulants; insufficient subcutaneous fat; lack of sexual interest. We used the following
outcome measurements. As described in (Olsen et al., 2015), the International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score (EHS) were used to assess erectile function before RP at study inclusion and 1, 3 and 6 months after ADRC treatment. Information on urinary incontinence was assessed by International Consultation on Incontinence Questionnaire – Urinary Incontinence – Short form questionnaire (ICIQ–UI SF). Adverse events were recorded at each visit by inspection of the injection site and posing the patients an open question, “Did you experience any discomfort related to the operation since the last visit?”, followed by specific questions regarding pain, bleeding and swelling at the liposuction site as well as at the penis area.

2.2. Approvals

The study was approved by the Danish National Ethics Committee (no. 37054), The Danish Health and Medicines Authority (EUDRA-CT number 2013–004220-11) and the Danish Data Protection Agency (2008–58-0035). The study was performed in accordance with the Declaration of Helsinki and ICH-GCP guidelines and monitored by the GCP Unit at Odense University Hospital. All patients gave written informed consent before participation. This study is registered at ClinicalTrials.gov (NCT02240823, Phase 1 Study. Can Fat Derived Stem Cells (SVF) be used in the Treatment of Erectile Dysfunction After Prostatectomy).

2.3. Procedures

2.3.1. Adipose Tissue Collection, ADRC Preparation, — Delivery and Characterization

Briefly, adipose tissue collection was conducted during general anesthesia, and harvesting was performed with water-jet-assisted liposuction. Following immediate isolation of ADRCs, using an automated processing Celution® 800/CRS system (Cytori Therapeutics, San Diego, California, USA), these were injected into corpus cavernosum. ADRCs were characterized by cell count, viability and subpopulation. For details, refer to supplementary material.

2.4. Statistical Analysis

This was an exploratory pilot study and no sample size estimates were calculated. We planned to include 30 patients with an interim efficacy analysis upon reaching 15 evaluable patients. In case of a clinically relevant positive signal at the interim analysis, the inclusion of patients would be discontinued at this point. Data are presented as medians and interquartile ranges (IQR) with exception of ADRC characteristics, which are mean (SD). IIEF outcomes were analyzed by repeated measurement two-way ANOVA with Sidak’s post-hoc test for multiple comparisons, following log transformation of data. Effect sizes are presented as geometric mean differences with 95% confidence intervals. EHS outcomes were analyzed by Friedman’s test for multiple non-parametric comparisons with Dunn’s post-hoc test for multiple comparisons. ICIQ–UI SF outcomes were analyzed by Wilcoxon’s matched pairs signed rank test. Associations between ADRCs and volume of liposuction and donor age were analyzed by Pearson’s product–moment correlation. ADRC phenotypes between groups were analyzed by the Mann–Whitney U test.

All statistical analyses were performed using Prism 6 (GraphPad Software, La Jolla, CA, USA).

2.5. Role of the Funding Source

The study sponsors had no role in the study design, data collection, data analysis, data interpretation or writing of the report. All authors had full access to all data. The corresponding author had final responsibility for the decision to submit for publication.

### Table 1

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>All patients (n = 17)</th>
<th>Continent (n = 11)</th>
<th>Incontinent (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>63.0 (9.0)</td>
<td>63.0 (10.0)</td>
<td>63.0 (5.8)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>30.3 (5.0)</td>
<td>28.7 (5.1)</td>
<td>30.7 (2.4)</td>
</tr>
<tr>
<td>Hypertensive</td>
<td>6</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Preoperative PSA, ng/ml</td>
<td>7.3 (5.4)</td>
<td>8.2 (5.1)</td>
<td>6.9 (3.2)</td>
</tr>
<tr>
<td>Surgical approach</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robotic prostatectomy</td>
<td>14</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Open retropercutaneous prostatectomy</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Nerve-sparing prostatectomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nerve-sparing RP</td>
<td>5</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>None nerve-sparing RP</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Pathologic stage</td>
<td>9</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>pT2c</td>
<td>15</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>pT3b</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Pathologic Gleason score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gleason 3 + 3</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Gleason 3 + 4</td>
<td>9</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Gleason 4 + 3</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Gleason 4 + 5</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Severe LUTS prior to diagnosis of prostate cancer.</td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

Data are median (IQR). *Severe LUTS defined as > 15 DANPSS points. DANPSS, Danish Validated Questionnaire on LUTS and LUTS-bother. PSA, Prostate Specific Antigens. RP, Radical Prostatectomy.

### 3. Results

We included 17 men (Fig. 1) aged between 46 and 69 years (63 (9), median (IQR)) years with ED after prostatectomy to intracavernosal injection with their own ADRCs freshly isolated after a liposuction. All patients had high IIEF-5 scores (23 (3), median (IQR)) and EHS scores (4 (1), median (IQR)), and reported an active sex life before RP. Eleven men were continent while 6 were incontinent at the time of inclusion, but baseline characteristics including age, BMI, smoking, alcohol intake, physical activity, degree of co-morbidities and medication were similar for the two groups (Table 1). Time between RP and ADRC treatment 10.1 (5.7) months with no difference (p = 0.2450, Mann–Whitney test) between continent and incontinent men is shown in Supplemental Fig. S1.

The characteristics of ADRCs isolated by the automated Celution® system (Table 2) were comparable to those previously reported for other ADRCs/SVF (Domenis et al., 2015) including yield (ADRCs/g fat tissue, 1.4 × 10⁶, 3.7 × 10⁶; mean, SD), cell size (10.7, 0.2; mean, SD), viability (84.7, 3.0; mean, SD) and, percentage of fibroblastoid colony forming units (%CFU-F, 1.5, 0.8; mean, SD). The number of ADRCs obtained per patient was strongly correlated to the amount of lipoaspirate (Fig. 2A), while we observed no relationship between age and yield per gram fat tissue (Fig. 2B). A large proportion of the freshly isolated ADRCs expressed the surface markers CD34 (67.3, 11.0%; mean, SD) and CD90 (71.3, 7.4%; mean, SD), whereas CD31 and CD73 each encompassed approximately 26% of the parent ADRCs (Fig. 2D), which is similar to what has been shown by others (Domenis et al., 2015; Aronowitz and Ellenhorn, 2013).

The men received between 8.4–37.2 million ADRCs immediately after cell isolation and were discharged from hospital the same day. No serious adverse events were reported. Five patients reported minor events related to the liposuction and ADRC injection at the one-month evaluation time point. Two men had experienced transient redness and swelling at the injection sites. One had a scrotal and penile hematoma that resolved within 14 days. This patient had taken large doses of NSAID medicine for back pain in the days before the treatment. Finally, 2 patients reported abdominal pain and tenderness for 2–6 days after
In ADRC characteristics between the groups of continent versus incontinent men (table 2). To estimate the rate of spontaneous reversal of ED post RP in our department, we reviewed the medical records for 2010–2013. These included records of 165 prostatectomized men with information about their sexual status and urine continence. There were 135 urine continent men and 30 incontinent men. In these groups, 40 and 4 men, respectively, reported having adequate sexual function, and were able to complete intercourse with or without medication 6 and 12 months after operation (Fig. 3F).

Additionally, urinary incontinence scores (ICIQ-UI SF) were significantly lower 6 months after ADRC injection in continent men (Dohner et al., 2015) (median (IQR)) (p = 0.0234, Wilcoxon matched pairs signed rank test) as compared to inclusion 3 (Tal et al., 2009) and a trend (8 (9) versus 12.5 (10.25)(p = 0.1875) was seen in incontinent men as well (Supplemental Fig. S2), suggesting that ADRC treatment may also have a positive effect on incontinence per se.

4. Discussion

In this clinical trial autologous non-expanded stem cells have been used for the treatment of ED following radical prostatectomy. In recent years, much attention has been given to stem cell-based therapies in general, and specifically in the field of urology where there has been a great deal of hype in relation to treatment of erectile dysfunction (ED) (Khera et al., 2015). Until now, there has been only one other published clinical trial reporting a beneficial effect of non-autologous umbilical cord cell transplantation in 3/7 men with type 2 DM (Bahk et al., 2013). Post-hoc stratification according to urine continence at inclusion revealed an apparent strong conditional association to the regain of function. Preliminary efficacy was solely demonstrated in the patients that were continent at inclusion (Fig. 3). In the continent group, the IIEF-5 score was unchanged 7 (Shabsigh et al., 2005) (median (IQR)) (p = 0.0069, RM one-way ANOVA with Sidak’s multiple comparisons test) as compared to inclusion 3 (Tal et al., 2009) (median (IQR)) (p = 0.0414) after 3 months and to 17 (Gimble et al., 2013) (0.66, (0.44–0.85), p = 0.0414) after 6 months (Fig. 3B). The EHS scores significantly increased at 6 months (3(1) (p = 0.0314, Friedman’s test) and a trend (8 (9) versus 12.5 (10.25)(p = 0.1875) was seen in incontinent men as well (Supplemental Fig. S2), suggesting that ADRC treatment may also have a positive effect on incontinence per se.

### Table 2
Characterization of the freshly isolated ADRCs.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All (n = 17)</th>
<th>Continent (n = 11)</th>
<th>Incontinent (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADRCs/mL liposuction</td>
<td>$1.3 \times 10^7$</td>
<td>$1.3 \times 10^7$</td>
<td>$1.2 \times 10^7$</td>
</tr>
<tr>
<td>ADRCs/g fat tissue</td>
<td>$1.4 \times 10^7$</td>
<td>$1.5 \times 10^7$</td>
<td>$1.3 \times 10^7$</td>
</tr>
<tr>
<td>Injected ADRCs</td>
<td>$2.2 \times 10^7$</td>
<td>$2.1 \times 10^7$</td>
<td>$2.3 \times 10^7$</td>
</tr>
<tr>
<td>Cell size (μm)</td>
<td>10.7 (0.2)</td>
<td>10.7 (0.2)</td>
<td>10.6 (0.2)</td>
</tr>
<tr>
<td>Viability (%)</td>
<td>84.7 (3.0)</td>
<td>85.3 (2.5)</td>
<td>83.8 (3.8)</td>
</tr>
<tr>
<td>CPU-F (%)</td>
<td>1.5 (0.8)</td>
<td>1.4 (0.8)</td>
<td>1.6 (0.7)</td>
</tr>
<tr>
<td>CD34 (%)</td>
<td>67.3 (11.0)</td>
<td>67.8 (12.2)</td>
<td>660.3 (9.3)</td>
</tr>
<tr>
<td>CD31 (%)</td>
<td>14.8 (6.4)</td>
<td>16.2 (6.2)</td>
<td>12.1 (6.5)</td>
</tr>
<tr>
<td>CD73 (%)</td>
<td>24.2 (12.1)</td>
<td>25.1 (13.0)</td>
<td>225 (11.2)</td>
</tr>
<tr>
<td>CD90 (%)</td>
<td>71.3 (7.4)</td>
<td>73.0 (5.7)</td>
<td>68.3 (9.6)</td>
</tr>
<tr>
<td>CFU-F (%)</td>
<td>1.5 (0.8)</td>
<td>1.4 (0.8)</td>
<td>1.6 (0.7)</td>
</tr>
<tr>
<td>Cell surface marker expression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD31-CD34+ ADRCs</td>
<td>identified</td>
<td>identified</td>
<td>identified</td>
</tr>
<tr>
<td>CD31-CD34-ADRCs</td>
<td>identified</td>
<td>identified</td>
<td>identified</td>
</tr>
<tr>
<td>Viability (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD31 (%)</td>
<td>14.8 (6.4)</td>
<td>16.2 (6.2)</td>
<td>12.1 (6.5)</td>
</tr>
<tr>
<td>CD73 (%)</td>
<td>24.2 (12.1)</td>
<td>25.1 (13.0)</td>
<td>225 (11.2)</td>
</tr>
<tr>
<td>CD90 (%)</td>
<td>71.3 (7.4)</td>
<td>73.0 (5.7)</td>
<td>68.3 (9.6)</td>
</tr>
</tbody>
</table>

* 1 ml = 0.9 g fat tissue. Data are mean (SD). Differences between groups were analyzed using Mann–Whitney test.
Earlier this year, this lack of substantial evidence from clinical trials led to a commentary in which Khera et al. raised their concerns regarding stem cell treatment of ED patients outside an approved protocol (Khera et al., 2015).

In this study, a single intracavernous injection of freshly isolated autologous ADRCs was a feasible, safe and well-tolerated approach for treating ED following radical prostatectomy. We did not observe any serious adverse events within a 6-month time frame, which – while clearly not sufficient for a long-term safety evaluation – nevertheless is reassuring. The safety from clinical trials encompassing more than 1000 patients receiving bone marrow or adipose tissue-derived mesenchymal stem/stromal cells, does not suggest that serious adverse events are a clinically important issue (Casiraghi et al., 2013). Importantly, post-hoc stratification demonstrated that the majority of continent men with ED after RP recovered erectile function within 3 months, and that this effect persisted for 6 months. This potential efficacy of the ADRC therapy was promisingly high, reaching 8/11 (73%). In contrast, such effect was absent in the group of incontinent men. These different outcomes are unlikely to result from underlying differences in the amount of injected stem cells or in their phenotypes, since all analyzed parameters were statistically equal between groups. However, the incontinent men may represent individuals where damage to the neurovascular bundle has resulted in partial disruption of urethral rhabdosphincter innervation as reported recently (Reeves et al., 2015). Also, it should be noted that these patients had lower inclusion IIEF5 and EHS scores compared to the continent group and that 5 of the 6 incontinent men were initially referred for prostate evaluation due to irritable lower urinary tract symptoms before the RP. This suggests that the incontinent men, have a more advanced neurovascular degeneration altogether which agrees with previous reports showing a difference in spontaneous recovery between continent and incontinent patients (Gandaglia et al., 2012). Finally, there is likely to be a psychological element, since incontinent men may feel less sexually attractive because of the incontinence. We believe the observation that incontinent men have no effect of ADRC therapy for ED is important for future studies and clinical decisions regarding which patient groups should be offered the therapy. ADRC therapy seems to partly alleviate the patient's urinary incontinence symptoms as measured by the ICIQ-UI SF scores (Supplemental Fig. S2). While the clinical significance thereof is unclear, these data are promising for treatment of incontinence per se.

Our results hold promise for the outcome of other ongoing clinical trials with stem cells for ED therapy, especially one trial in RP patients using allogeneic cultured stem cells derived from bone marrow (NCT01983709), and for tests of mesenchymal stem cells in a wide range of human diseases. For evaluation of the clinical impact, it will be important to characterize the quality, stability and potency of different types and preparations of mesenchymal stem cells. For instance, it is not known if cultured ADRCs or ADRCs from another person, other mesenchymal stem cells or even induced pluripotent stem (iPS) cells would work as well as the freshly isolated stem cells used herein. If cultured non-autologous ADRCs or iPS cells work equally well both from a safety and efficacy point of view, this would have a large impact for the field since cells from stem cell banks could then be used. We investigated ED after RP, which is considered a severe form of ED with nerve injury; however, it is not known if stem cell therapy would work in patients with ED due to diabetes, cardiovascular disease, lower urinary tract diseases or simply age. Our results as well as results from the Korean study in diabetic men (Bahk et al., 2010) suggest that stem cell therapy may be effective for different types of ED.

Our study has several limitations. This pilot study was unblinded without a control group. We cannot discern if the positive effect is a result of the urologist interviews or the patient’s own expectations to stem cell therapy or if in fact the stem cells themselves by differentiation have helped regenerate the erectile function (Gimble et al., 2013; Zuk.
2010) or if a paracrine mechanism is responsible (Fandel et al., 2012; Kimbrel et al., 2014). In general, reported degrees of ED after RP vary greatly (14%–86%) depending on risk stratification and patient selection, the experience of the surgeon, type of operation and the measure and definition of ED (Weyne and Albersen, 2014). The result that 8/11 (73%) of the continent men recovered erectile function after ADRC therapy is promising, although further placebo-controlled trials are needed to differentiate possible stem cell effects from spontaneous regeneration. Regarding spontaneous regeneration, background data from review of 165 medical journals from our urology department showed that only 40/135 (29.6%) continent men and 4/30 (13.3%) incontinent men recovered their erectile function 6 months and 1 year after RP using conventional therapy. In a previous RCT study of much milder forms of ED from our group (Olsen et al., 2015), only 7/57 (12.3%) men in a placebo control group recovered erectile function (IIEF scores above 10) after 6 months. Likewise, others have analyzed all 11 reported, randomized, controlled trials to enclose a penile rehabilitation of 20–25% following RP (Schauer et al., 2015). In the present paper, we report that a much higher number of the stem cell-treated RP-induced ED men with urinary continence had high IIEF scores after 6 months. Finally, the nine months’ IIEF score data from 423 men with ED after RP in the REACTT placebo-controlled study showed relatively low recovery of erectile function after RP; 25.5% had high IIEF scores in the “5 mg tadalafil (Cialis®) 3 times a day group” versus 14.2% with high IIEF scores in the placebo group (Montorsi et al., 2014).

We did not include objective measurement for the recovery of erectile function, like measurements of penile hemodynamics or nerve impulse speed. We used EHS and IIEF scores that are generated on the basis of patient questionnaires and thus could be biased by several factors including interviewer effects and differences in the patients’ understanding of the questions. In order to mitigate interviewer bias, we used the same interviewer throughout the study, and interviewed the patients at different time points using the same questions. A recent study shows correlation between objective measurements and EHS (Matsuda et al., 2014).

In conclusion, our findings suggest that autologous, freshly isolated ADRCs are safe to use and possess potential efficacy in the treatment of ED after RP. These findings need confirmation in an adequately powered, randomized and placebo-controlled trial.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ebiom.2016.01.024.

5. Contributors

MKH and CHJ contributed equally to this work. Literature search: MKH, CHJ, SPS; Conception: SPS; Design: SPS, LL, MKH, CHJ, PD; Recruitment: MKH, LL; Surgical procedures: JAS, NT, MKH; Cell processing and laboratory procedures: CHJ; Data Collection: MKH, CHJ; Data analysis and interpretation: SPS, DCA, CHJ, MKH, PD; Production of figures and tables: SPS, CHJ, DCA, MKH. Manuscript writing: SPS, DCA, CHJ, MKH, PD. All authors have contributed to review and revision and approved the final manuscript version.

Conflicts of Interest

SPS has asked the Danish Health Authorities for permission to offer the treatment to the public in a private hospital. All other authors declare no conflicts of interest.

Interpretation

Our pilot data suggest that a single intracavernous injection of freshly isolated autologous ADRCs is a safe, and potentially efficient treatment of ED following radical prostatectomy. These results suggest that ADSCs can restore normal erectile function and such therapy may become a significant in the treatment of ED. Our results hold promise for the outcome of other ongoing clinical trials with stem cells for ED therapy, especially one trial in RP patients using allogeneic, cultured stem cells derived from bone marrow (NCT01983709), and for tests of mesenchymal stem cells in a wide range of human diseases.

Acknowledgment

This study was funded by Odense University Hospital (11/31936), The Danish Centre for Regenerative Medicine (14/50427) and the Danish Cancer Society. We thank Lars Melholt Rasmussen, prof. MD, Odense University Hospital and Bruce Conklin, MD, PhD, The Gladstone Inst. USCF, San Francisco, USA for critical reading of the manuscript.

References


Reeves, F., Everaerts, W., Murphy, D.G., et al., 2015. Stimulation of the Neurovascular Bundle Results in Rhabdosphincter Contraction in a Proportion of Men Undergoing Radical Prostatectomy. Urology.


